The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients - Full Text View

The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients

This study has been completed.

Sponsored by:	Mucos Pharma GmbH and Co
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002311

Purpose

To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.

Condition	Intervention	Phase
HIV Infections	Drug: Wobenzym	Phase I

MedlinePlus related topics:

AIDS

Drug Information available for:

Wobenzym

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Dose Comparison, Pharmacokinetics Study

Official Title:	A Phase I-II Dose Escalation Study to Examine the Safety of Four Doses of Wobenzym in HIV Seropositive Patients

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients must have:

HIV seropositivity with CD4 counts between 250 and 400 cells/mm3.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

Known hypersensitivity to hydrolytic enzymes such as Wobenzym.
Known sensitivity to lactose.
Presumption that the patient will not comply with the dosing schedule or follow-up appointments.

Concurrent Medication:

Excluded:

Concurrent use of immunosuppressive therapy or steroids.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002311

Locations


United States, New York
	Saint Luke's - Roosevelt Hosp Ctr
	New York, New York, United States, 10019

Sponsors and Collaborators

Mucos Pharma GmbH and Co

More Information

Study ID Numbers:	122A
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002311
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Acquired Immunodeficiency Syndrome

AIDS-Related Complex

Wobenzym

Hydrolases

Study placed in the following topic categories:

Virus Diseases

Sexually Transmitted Diseases, Viral

HIV Seropositivity

HIV Infections

Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome

Wobenzym

AIDS-Related Complex

Retroviridae Infections

Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

RNA Virus Infections

Slow Virus Diseases

Immunologic Factors

Immune System Diseases

Physiological Effects of Drugs

Adjuvants, Immunologic

Lentivirus Infections

Infection

Pharmacologic Actions

ClinicalTrials.gov processed this record on December 03, 2008